Business Description
Amedisys Inc
NAICS : 621610
SIC : 8082
ISIN : US0234361089
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.32 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.42 | |||||
Debt-to-EBITDA | 2.03 | |||||
Interest Coverage | 6.48 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 3.95 | |||||
Beneish M-Score | -2.15 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.3 | |||||
3-Year EBITDA Growth Rate | -23.2 | |||||
3-Year EPS without NRI Growth Rate | -9 | |||||
3-Year FCF Growth Rate | -23.5 | |||||
3-Year Book Growth Rate | 9.8 | |||||
Future 3-5Y EPS without NRI Growth Rate | 8.1 | |||||
Future 3-5Y Total Revenue Growth Rate | 7.01 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 86.53 | |||||
9-Day RSI | 69.61 | |||||
14-Day RSI | 59.42 | |||||
6-1 Month Momentum % | 2.96 | |||||
12-1 Month Momentum % | 0.58 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.16 | |||||
Quick Ratio | 1.16 | |||||
Cash Ratio | 0.31 | |||||
Days Sales Outstanding | 51.91 | |||||
Days Payable | 9.35 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.1 | |||||
Shareholder Yield % | 1.3 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 44.03 | |||||
Operating Margin % | 9.13 | |||||
Net Margin % | 4.02 | |||||
FCF Margin % | 3.84 | |||||
ROE % | 8.63 | |||||
ROA % | 4.48 | |||||
ROIC % | 8.2 | |||||
ROC (Joel Greenblatt) % | 128.93 | |||||
ROCE % | 11.12 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 34.51 | |||||
Forward PE Ratio | 18.91 | |||||
PE Ratio without NRI | 22.63 | |||||
Shiller PE Ratio | 30.88 | |||||
Price-to-Owner-Earnings | 55.76 | |||||
PS Ratio | 1.39 | |||||
PB Ratio | 2.81 | |||||
Price-to-Free-Cash-Flow | 35.83 | |||||
Price-to-Operating-Cash-Flow | 32.95 | |||||
EV-to-EBIT | 19.84 | |||||
EV-to-Forward-EBIT | 14.64 | |||||
EV-to-EBITDA | 14.88 | |||||
EV-to-Forward-EBITDA | 12.71 | |||||
EV-to-Revenue | 1.52 | |||||
EV-to-Forward-Revenue | 1.31 | |||||
EV-to-FCF | 39.43 | |||||
Price-to-Projected-FCF | 1.21 | |||||
Price-to-Median-PS-Value | 0.99 | |||||
Earnings Yield (Greenblatt) % | 5.04 | |||||
FCF Yield % | 2.8 | |||||
Forward Rate of Return (Yacktman) % | -3.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Amedisys Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 2,119.521 | ||
EPS (TTM) (€) | 2.596 | ||
Beta | 1.03 | ||
Volatility % | 8.19 | ||
14-Day RSI | 59.42 | ||
14-Day ATR (€) | 0.469324 | ||
20-Day SMA (€) | 86.125 | ||
12-1 Month Momentum % | 0.58 | ||
52-Week Range (€) | 82.5 - 89.5 | ||
Shares Outstanding (Mil) | 32.74 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Amedisys Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Amedisys Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Amedisys Inc Frequently Asked Questions
What is Amedisys Inc(STU:ADY)'s stock price today?
When is next earnings date of Amedisys Inc(STU:ADY)?
Does Amedisys Inc(STU:ADY) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |